Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023)

Gastaldi, Giacomo; Lucchini, Barbara; Thalmann, Sebastien; Alder, Stephanie; Laimer, Markus; Brändle, Michael; Wiesli, Peter; Lehmann, Roger; Working group of the SGED/SSED

doi:10.57187/smw.2023.40060

Citations

Citation copied

Gastaldi, G., Lucchini, B., Thalmann, S., Alder, S., Laimer, M., Brändle, M., Wiesli, P., Lehmann, R., & Working group of the SGED/SSED. (2023). Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023). Swiss Medical Weekly, 153(4), 40060. https://doi.org/10.57187/smw.2023.40060

Abstract

As a first step, the authors emphasise lifestyle changes (increased physical activity, stopping smoking), blood pressure control, and lowering cholesterol). The initial medical treatment should always be a combination treatment with metformin and a sodium-glucose transporter 2 (SGLT-2) inhibitor or a glucagon-like 1 peptide (GLP-1) receptor agonist. Metformin is given first and up-titrated, followed by SGLT-2 inhibitors or GLP-1 receptor agonists. In persons with type 2 diabetes, if the initial double combination is not sufficient, a